Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Jun;73(12):1486–1490. doi: 10.1038/bjc.1996.281

Urinary gonadotropin peptide (UGP) in Egyptian patients with benign and advanced malignant urological disease.

O el-Ahmady 1, A B Halim 1, O Mansour 1, T Salman 1, A G el-Din 1, R P Walker 1
PMCID: PMC2074546  PMID: 8664117

Abstract

Urinary gonadotropin peptide (UGP) levels were determined in urine samples from 450 Egyptian subjects to determine its relative level of expression in benign and malignant urological disease, and normal individuals. The mean UGP level in patients with bladder cancer was 44-fold higher than in patients with benign disease, and 81-fold higher than in normal individuals. At specificities of 95% and 100%, overall sensitivities of 73% and 60%, respectively, were observed for the detection of malignant disease. Mean UGP levels in patients with bladder cancer were significantly correlated with the stage and grade of malignant disease but did not vary significantly when stratified according to histological type of disease, nodal involvement or bilharzial association. UGP could be a potentially useful marker for the differentiation of benign from malignant urological disease.

Full text

PDF
1486

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Al-Shukri S., Alwan M. H., Nayef M., Rahman A. A. Bilharziasis in malignant tumours of the urinary bladder. Br J Urol. 1987 Jan;59(1):59–62. doi: 10.1111/j.1464-410x.1987.tb04580.x. [DOI] [PubMed] [Google Scholar]
  2. Alfthan H., Haglund C., Roberts P., Stenman U. H. Elevation of free beta subunit of human choriogonadotropin and core beta fragment of human choriogonadotropin in the serum and urine of patients with malignant pancreatic and biliary disease. Cancer Res. 1992 Sep 1;52(17):4628–4633. [PubMed] [Google Scholar]
  3. Birken S., Armstrong E. G., Kolks M. A., Cole L. A., Agosto G. M., Krichevsky A., Vaitukaitis J. L., Canfield R. E. Structure of the human chorionic gonadotropin beta-subunit fragment from pregnancy urine. Endocrinology. 1988 Jul;123(1):572–583. doi: 10.1210/endo-123-1-572. [DOI] [PubMed] [Google Scholar]
  4. Blithe D. L., Wehmann R. E., Nisula B. C. Carbohydrate composition of beta-core. Endocrinology. 1989 Nov;125(5):2267–2272. doi: 10.1210/endo-125-5-2267. [DOI] [PubMed] [Google Scholar]
  5. Cole L. A., Nam J. H. Urinary gonadotropin fragment (UGF) measurements in the diagnosis and management of ovarian cancer. Yale J Biol Med. 1989 Jul-Aug;62(4):367–378. [PMC free article] [PubMed] [Google Scholar]
  6. Endo T., Nishimura R., Saito S., Kanazawa K., Nomura K., Katsuno M., Shii K., Mukhopadhyay K., Baba S., Kobata A. Carbohydrate structures of beta-core fragment of human chorionic gonadotropin isolated from a pregnant individual. Endocrinology. 1992 Apr;130(4):2052–2058. doi: 10.1210/endo.130.4.1547728. [DOI] [PubMed] [Google Scholar]
  7. Franchimont P., Gaspard U., Reuter A., Heynen G. Polymorphism of protein and polypeptide hormones. Clin Endocrinol (Oxf) 1972 Oct;1(4):315–336. doi: 10.1111/j.1365-2265.1972.tb00402.x. [DOI] [PubMed] [Google Scholar]
  8. Halim A. B., Barakat M., el-Zayat A. M., Daw M., el-Ahmady O. Urinary beta-HCG in benign and malignant urinary tract diseases. Dis Markers. 1995 Mar;12(2):109–115. doi: 10.1155/1994/179287. [DOI] [PubMed] [Google Scholar]
  9. Halim A. B., el-Ahmady O., Hamza S., Aboul-Ela M., Oehr P. Serum TPS versus TPA in Egyptian bladder cancer patients. Int J Biol Markers. 1993 Oct-Dec;8(4):221–226. doi: 10.1177/172460089300800404. [DOI] [PubMed] [Google Scholar]
  10. Halim A. B., el-Ahmady O., Hamza S., Aboul-Ela M., Oehr P. Simultaneous determination of urinary CEA, ferritin and TPA in Egyptian bladder cancer patients. Int J Biol Markers. 1992 Oct-Dec;7(4):234–239. doi: 10.1177/172460089200700406. [DOI] [PubMed] [Google Scholar]
  11. Iles R. K., Lee C. L., Oliver R. T., Chard T. Composition of intact hormone and free subunits in the human chorionic gonadotrophin-like material found in serum and urine of patients with carcinoma of the bladder. Clin Endocrinol (Oxf) 1990 Sep;33(3):355–364. doi: 10.1111/j.1365-2265.1990.tb00500.x. [DOI] [PubMed] [Google Scholar]
  12. Kardana A., Taylor M. E., Southall P. J., Boxer G. M., Rowan A. J., Bagshawe K. D. Urinary gonadotrophin peptide--isolation and purification, and its immunohistochemical distribution in normal and neoplastic tissues. Br J Cancer. 1988 Sep;58(3):281–286. doi: 10.1038/bjc.1988.204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kato Y., Braunstein G. D. Beta-core fragment is a major form of immunoreactive urinary chorionic gonadotropin in human pregnancy. J Clin Endocrinol Metab. 1988 Jun;66(6):1197–1201. doi: 10.1210/jcem-66-6-1197. [DOI] [PubMed] [Google Scholar]
  14. Lee C. L., Iles R. K., Shepherd J. H., Hudson C. N., Chard T. The purification and development of a radioimmunoassay for beta-core fragment of human chorionic gonadotrophin in urine: application as a marker of gynaecological cancer in premenopausal and postmenopausal women. J Endocrinol. 1991 Sep;130(3):481–489. doi: 10.1677/joe.0.1300481. [DOI] [PubMed] [Google Scholar]
  15. MUSTACCHI P., SHIMKIN M. B. Cancer of the bladder and infestation with Schistosoma hematobium. J Natl Cancer Inst. 1958 Apr;20(4):825–842. [PubMed] [Google Scholar]
  16. Nam J. H., Chambers J. T., Schwartz P. E., Cole L. A. Urinary gonadotropin fragment, a new tumor marker. IV. Use in endometrial cancers and uterine mixed mullerian tumors. Gynecol Oncol. 1990 Dec;39(3):352–357. doi: 10.1016/0090-8258(90)90265-m. [DOI] [PubMed] [Google Scholar]
  17. Nam J. H., Chang K. C., Chambers J. T., Schwartz P. E., Cole L. A. Urinary gonadotropin fragment, a new tumor marker. III. Use in cervical and vulvar cancers. Gynecol Oncol. 1990 Jul;38(1):66–70. doi: 10.1016/0090-8258(90)90013-b. [DOI] [PubMed] [Google Scholar]
  18. Norman R. J., Buck R. H., Aktar B., Mayet N., Moodley J. Detection of a small molecular species of human chorionic gonadotropin in the urine of patients with carcinoma of the cervix and cervical intraepithelial neoplasia: comparison with other assays for human chorionic gonadotropin and its fragments. Gynecol Oncol. 1990 May;37(2):254–259. doi: 10.1016/0090-8258(90)90343-j. [DOI] [PubMed] [Google Scholar]
  19. Oliver R. T., Stephenson C., Collino C. E., Parkinson M. C. Clinicopathological significance of immunoreactive beta-hCG production by bladder cancer. Mol Biother. 1988;1(1):43–45. [PubMed] [Google Scholar]
  20. Papapetrou P. D., Sakarelou N. P., Braouzi H., Fessas P. Ectopic production of human chorionic gonadotropin (hCG) by neoplasms: the value of measurements of immunoreactive hCG in the urine as a screening procedure. Cancer. 1980 May 15;45(10):2583–2592. doi: 10.1002/1097-0142(19800515)45:10<2583::aid-cncr2820451018>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  21. Yoshimura M., Nishimura R., Murotani A., Miyamoto Y., Nakagawa T., Hasegawa K., Koizumi T., Shii K., Baba S., Tsubota N. Assessment of urinary beta-core fragment of human chorionic gonadotropin as a new tumor marker of lung cancer. Cancer. 1994 Jun 1;73(11):2745–2752. doi: 10.1002/1097-0142(19940601)73:11<2745::aid-cncr2820731116>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  22. de Medeiros S. F., Amato F., Norman R. J. Stability of immunoreactive beta-core fragment of hCG. Obstet Gynecol. 1991 Jan;77(1):53–59. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES